Kimberly R Jenkins1, Taofik Oyekunle1,2, Lauren E Howard1,2, Emily K Wiggins1, Stephen J Freedland1,3, Emma H Allott4,5. 1. Division of Urology, Veterans Affairs Medical Center, Durham, NC, USA. 2. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. 3. Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. 4. Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Room 2.15, Belfast, BT9 7AE, UK. e.allott@qub.ac.uk. 5. Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. e.allott@qub.ac.uk.
Abstract
PURPOSE: To test for racial differences in associations between family history (FH) of prostate cancer (PC) and prostate cancer aggressiveness in a racially diverse equal access population undergoing prostate biopsy. SUBJECTS/PATIENTS AND METHODS: We prospectively enrolled men undergoing prostate biopsy at the Durham Veterans Administration from 2007 to 2018 and assigned case or control status based on biopsy results. Race and FH of PC were self-reported on questionnaires. Logistic regression was used to test the association between FH and PC diagnosis overall and by tumor aggressiveness [high- (Grade Group 3-5) or low-grade (Grade Group 1-2) vs. no cancer], overall, and stratified by race. Models were adjusted for age and year of consent, race, PSA level, digital rectal exam findings, prostate volume, and previous (negative) biopsy receipt. RESULTS: Of 1,225 men, 323 had a FH of PC and 652 men were diagnosed with PC on biopsy. On multivariable analysis, FH was associated with increased odds of high-grade PC in black (OR 1.85, p = 0.041) and all men (OR 1.56, p = 0.057) and was unrelated to overall or low-grade PC diagnosis, overall, or stratified by race (all p ≥ 0.325). In sensitivity analyses among men without a previous biopsy, results were slightly more pronounced. CONCLUSION: In this setting of equal access to care, positive FH of PC was associated with increased tumor aggressiveness in black men, but not non-black men undergoing prostate biopsy. Further research is required to tease apart the contribution of genetics from increased PC awareness potentially influencing screening and biopsy rates in men with FH.
PURPOSE: To test for racial differences in associations between family history (FH) of prostate cancer (PC) and prostate cancer aggressiveness in a racially diverse equal access population undergoing prostate biopsy. SUBJECTS/PATIENTS AND METHODS: We prospectively enrolled men undergoing prostate biopsy at the Durham Veterans Administration from 2007 to 2018 and assigned case or control status based on biopsy results. Race and FH of PC were self-reported on questionnaires. Logistic regression was used to test the association between FH and PC diagnosis overall and by tumor aggressiveness [high- (Grade Group 3-5) or low-grade (Grade Group 1-2) vs. no cancer], overall, and stratified by race. Models were adjusted for age and year of consent, race, PSA level, digital rectal exam findings, prostate volume, and previous (negative) biopsy receipt. RESULTS: Of 1,225 men, 323 had a FH of PC and 652 men were diagnosed with PC on biopsy. On multivariable analysis, FH was associated with increased odds of high-grade PC in black (OR 1.85, p = 0.041) and all men (OR 1.56, p = 0.057) and was unrelated to overall or low-grade PC diagnosis, overall, or stratified by race (all p ≥ 0.325). In sensitivity analyses among men without a previous biopsy, results were slightly more pronounced. CONCLUSION: In this setting of equal access to care, positive FH of PC was associated with increased tumor aggressiveness in black men, but not non-black men undergoing prostate biopsy. Further research is required to tease apart the contribution of genetics from increased PC awareness potentially influencing screening and biopsy rates in men with FH.
Entities:
Keywords:
African American; Family history of prostate cancer; Prostate biopsy; Prostate cancer; Tumor grade
Authors: J-A Thomas; L Gerber; D M Moreira; R J Hamilton; L L Bañez; R Castro-Santamaria; G L Andriole; W B Isaacs; J Xu; S J Freedland Journal: J Intern Med Date: 2012-01-16 Impact factor: 8.989
Authors: Irene M Shui; Sara Lindström; Adam S Kibel; Sonja I Berndt; Daniele Campa; Travis Gerke; Kathryn L Penney; Demetrius Albanes; Christine Berg; H Bas Bueno-de-Mesquita; Stephen Chanock; E David Crawford; W Ryan Diver; Susan M Gapstur; J Michael Gaziano; Graham G Giles; Brian Henderson; Robert Hoover; Mattias Johansson; Loic Le Marchand; Jing Ma; Carmen Navarro; Kim Overvad; Fredrick R Schumacher; Gianluca Severi; Afshan Siddiq; Meir Stampfer; Victoria L Stevens; Ruth C Travis; Dimitrios Trichopoulos; Paolo Vineis; Lorelei A Mucci; Meredith Yeager; Edward Giovannucci; Peter Kraft Journal: Eur Urol Date: 2014-01-04 Impact factor: 20.096
Authors: Victor Virlogeux; Rebecca E Graff; Thomas J Hoffmann; John S Witte Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-03-25 Impact factor: 4.254
Authors: Tisheeka Graham-Steed; Edward Uchio; Carolyn K Wells; Mihaela Aslan; John Ko; John Concato Journal: Am J Med Date: 2013-12 Impact factor: 4.965
Authors: A S Whittemore; A H Wu; L N Kolonel; E M John; R P Gallagher; G R Howe; D W West; C Z Teh; T Stamey Journal: Am J Epidemiol Date: 1995-04-15 Impact factor: 4.897
Authors: Alexander Gusev; Huwenbo Shi; Gleb Kichaev; Mark Pomerantz; Fugen Li; Henry W Long; Sue A Ingles; Rick A Kittles; Sara S Strom; Benjamin A Rybicki; Barbara Nemesure; William B Isaacs; Wei Zheng; Curtis A Pettaway; Edward D Yeboah; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Ann Truelove; Shelley Niwa; Anand P Chokkalingam; Esther M John; Adam B Murphy; Lisa B Signorello; John Carpten; M Cristina Leske; Suh-Yuh Wu; Anslem J M Hennis; Christine Neslund-Dudas; Ann W Hsing; Lisa Chu; Phyllis J Goodman; Eric A Klein; John S Witte; Graham Casey; Sam Kaggwa; Michael B Cook; Daniel O Stram; William J Blot; Rosalind A Eeles; Douglas Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch; Kenneth Muir; Graham G Giles; Melissa C Southey; Liesel M Fitzgerald; Henrik Gronberg; Fredrik Wiklund; Markus Aly; Brian E Henderson; Johanna Schleutker; Tiina Wahlfors; Teuvo L J Tammela; Børge G Nordestgaard; Tim J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokolorczyk; Wojciech Kluzniak; Lisa Cannon-Albright; Craig Teerlink; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Amanda Spurdle; Judith A Clements; Manuel R Teixeira; Hardev Pandha; Agnieszka Michael; Paula Paulo; Sofia Maia; Andrzej Kierzek; David V Conti; Demetrius Albanes; Christine Berg; Sonja I Berndt; Daniele Campa; E David Crawford; W Ryan Diver; Susan M Gapstur; J Michael Gaziano; Edward Giovannucci; Robert Hoover; David J Hunter; Mattias Johansson; Peter Kraft; Loic Le Marchand; Sara Lindström; Carmen Navarro; Kim Overvad; Elio Riboli; Afshan Siddiq; Victoria L Stevens; Dimitrios Trichopoulos; Paolo Vineis; Meredith Yeager; Gosia Trynka; Soumya Raychaudhuri; Frederick R Schumacher; Alkes L Price; Matthew L Freedman; Christopher A Haiman; Bogdan Pasaniuc Journal: Nat Commun Date: 2016-04-07 Impact factor: 14.919